Javascript must be enabled to continue!
Analysis of topoisomerase II‐mediated DNA cleavage of the c‐myc gene during HL60 differentiation
View through CrossRef
We have investigated the effect of mAMSA, a potent topoisomerase II inhibitor, on the c‐myc proto‐oncogene of the acute promyelocytic leukemia HL60 cell line during its differentiation. When HL60 cells were induced by dimethylsulfoxide (DMSO) to terminally differentiate, a rapid drop in the level of cmyc mRNA was observed, followed by an arrest of cell proliferation. In contrast, the level of topoisomerase II mRNA was transiently increased with a maximum at 6 h after DMSO addition and was then completely abolished after 48 h, indicating that topoisomerase II is activated during the onset of HL60 differentiation. In exponentially growing cells, treatment by mAMSA results in the formation of topoisomerase II‐mediated double strand DNA breaks in the c‐myc gene at positions where topoisomerase II would normally nick and reseal the two strands. In HL60 cells treated with both mAMSA and DMSO, the sites in the cmyc gene at which mAMSA had induced cleavage were not altered. However, a DNA cleavage site located at the end of the first c‐myc exon (position +3100), was strongly stimulated by mAMSA and DMSO treatment. This site fell within a DNase I hypersensitive region encompassing the MYC intron factor 1 (MIF1) binding site, where transcription elongation is normally blocked during differentiation. These data indicate that a change of topoisomerase II binding to critical regulatory region of the c‐myc gene is associated with the downregulation of this gene during differentiation.
Title: Analysis of topoisomerase II‐mediated DNA cleavage of the c‐myc gene during HL60 differentiation
Description:
We have investigated the effect of mAMSA, a potent topoisomerase II inhibitor, on the c‐myc proto‐oncogene of the acute promyelocytic leukemia HL60 cell line during its differentiation.
When HL60 cells were induced by dimethylsulfoxide (DMSO) to terminally differentiate, a rapid drop in the level of cmyc mRNA was observed, followed by an arrest of cell proliferation.
In contrast, the level of topoisomerase II mRNA was transiently increased with a maximum at 6 h after DMSO addition and was then completely abolished after 48 h, indicating that topoisomerase II is activated during the onset of HL60 differentiation.
In exponentially growing cells, treatment by mAMSA results in the formation of topoisomerase II‐mediated double strand DNA breaks in the c‐myc gene at positions where topoisomerase II would normally nick and reseal the two strands.
In HL60 cells treated with both mAMSA and DMSO, the sites in the cmyc gene at which mAMSA had induced cleavage were not altered.
However, a DNA cleavage site located at the end of the first c‐myc exon (position +3100), was strongly stimulated by mAMSA and DMSO treatment.
This site fell within a DNase I hypersensitive region encompassing the MYC intron factor 1 (MIF1) binding site, where transcription elongation is normally blocked during differentiation.
These data indicate that a change of topoisomerase II binding to critical regulatory region of the c‐myc gene is associated with the downregulation of this gene during differentiation.
Related Results
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract
Medulloblastoma (MB), the most common malignant pediatric brain tumor, results in significant neurological, intellectual and physical disability or death. F...
Topoisomerase Assays
Topoisomerase Assays
AbstractTopoisomerases are enzymes that play essential roles in DNA replication, transcription, chromosome segregation, and recombination. All cells have two major forms of DNA top...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract
MYC activation and dysregulation is a powerful oncogenic driver in multiple cancers, including diffuse large B cell lymphoma (DLBCL). There is a known corre...
Abstract 1275: MK591 (Quiflapon) downregulates c-Myc oncogenic signaling and induces apoptosis in enzalutamide-resistant prostate cancer cells
Abstract 1275: MK591 (Quiflapon) downregulates c-Myc oncogenic signaling and induces apoptosis in enzalutamide-resistant prostate cancer cells
Abstract
Background: Enzalutamide is an FDA-approved drug commonly prescribed for advanced prostate cancer. Enzalutamide slows down prostate tumor growth but resista...
Abstract 3333: Cancer stem cell-mediated regulation of Myc overexpressing medulloblastoma cells on proliferation, migration and invasion
Abstract 3333: Cancer stem cell-mediated regulation of Myc overexpressing medulloblastoma cells on proliferation, migration and invasion
Abstract
Medulloblastoma (MB) is the most common and malignant pediatric brain tumor. Myc amplification was frequently shown in the tumor. Hereby cancer stem cells a...

